Skip to content

PBRER (Periodic Benefit-Risk Evaluation Report)

Last reviewed

A Periodic Benefit-Risk Evaluation Report (PBRER) is the post-approval periodic report in which a marketing authorisation holder evaluates new safety information in the context of a product's cumulative benefit-risk profile. It is defined in ICH E2C(R2) and replaced the earlier PSUR format.

Key facts

GuidelineICH E2C(R2)
Applies toApproved medicines
FrequencyEvery 6 or 12 months, or less often, depending on the product and the region
DueWithin 70 calendar days of the data lock point for reports covering 6 or 12 months; within 90 calendar days for intervals longer than 12 months
Reference informationThe latest Company Core Data Sheet (CCDS) is a practical option; otherwise another document such as the USPI or EU SmPC
EU namePSUR

What a PBRER contains

The report covers worldwide marketing status, estimated exposure, summary tabulations, signals evaluated during the interval, an evaluation of risks and of benefits, and an integrated benefit-risk analysis for the approved indications.

Sources

Read more